^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azacitidine

    i
    Other names: U-18496, Aza-C, NS 17, NS-17, Aza C, NSC-102816
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    3d
    VENETACIBLE: Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven (clinicaltrials.gov)
    P=N/A, N=20, Completed, Centre Hospitalier Universitaire de Nice | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Mar 2025
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    3d
    Transcription Activation of DEPDC1B Upon EBF1 Loss Contributes to Cell Cycle Progression and Epithelial-Mesenchymal Transition in Colon Adenocarcinoma. (PubMed, Biochem Genet)
    EBF1 presented a promoter hypermethylation pattern in COAD cell lines, in which its expression was restored upon treatment of the methylation inhibitor 5-azacytidine. In conclusion, this study highlights that the hypermethylation of EBF1 leads to transcription activation of DEPDC1B, which promotes cell cycle progression, EMT, and malignant progression in COAD. Restoring EBF1 levels or suppressing DEPDC1B expression may be promising strategies for COAD management.
    Journal
    |
    EBF1 (EBF Transcription Factor 1)
    |
    azacitidine
    4d
    Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia. (PubMed, Blood)
    Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) depend on oxidative phosphorylation (OXPHOS) sustained by fatty acid oxidation (FAO) and mitochondrial fusion (mitofusion). In vivo, miRisten potentiated the VEN/azacitidine (AZA) regimen, an FDA-approved therapy for older or unfit AML patients, significantly prolonging survival in patient-derived xenograft models. VEN/miRisten combination also reduced LSC burden and restored VEN sensitivity, establishing miR-126 inhibition as a transformative therapeutic strategy in AML.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MIR126 (MicroRNA 126)
    |
    Venclexta (venetoclax) • azacitidine
    8d
    Pan-cancer analysis of the oncogenic role of SRY-related high-mobility group box protein B5 in human tumors. (PubMed, Exp Ther Med)
    Moreover, SOX5 was associated with genomic instability, susceptibility to medicines such as azacitidine and distinct mutation patterns. SOX5 suppression in NSCLC cells in vitro impeded proliferation, migration and invasion. These findings collectively emphasize the key function of SOX5 in tumor biology and highlight its potential as a biomarker for cancer diagnosis, prognosis and therapeutic targeting.
    Journal • PD(L)-1 Biomarker • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    azacitidine
    8d
    Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Aug 2026 --> Oct 2025
    Trial primary completion date
    |
    azacitidine • Synribo (omacetaxine mepesuccinate)
    8d
    Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    azacitidine • Xpovio (selinexor)
    9d
    Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=57, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed
    Trial completion
    |
    azacitidine • sirolimus
    10d
    Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group. (PubMed, PeerJ)
    Idarubicin, cytarabine, etoposide (IA ± E) chemotherapy yielded superior survival, while azacitidine+venetoclax (AZA+VEN) regimens underperformed. The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).
    Clinical data • Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    TP53 mutation • FLT3 mutation • NPM1 mutation • KIT mutation • TET2 mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • idarubicin hydrochloride
    10d
    Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. (PubMed, Trials)
    This study aims to demonstrate that ABC-14 regimen is non-inferior to "3 + 7" regimen in newly diagnosed AML induction therapy while overcoming AB resistance and reducing toxicity associated with "3 + 7". It seeks to provide a broadly applicable alternative induction strategy for AML.
    Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • MCL1 (Myeloid cell leukemia 1)
    |
    TP53 mutation • FLT3-ITD mutation
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    10d
    A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    10d
    CONFIDHENCE: Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC (clinicaltrials.gov)
    P=N/A, N=8, Completed, iOMEDICO AG | Recruiting --> Completed | N=100 --> 8 | Trial completion date: Dec 2028 --> Jul 2025 | Trial primary completion date: Jun 2028 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    azacitidine • Tibsovo (ivosidenib)
    11d
    22P.205: Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Thomas Jefferson University | Phase classification: P1/2 --> P1
    Phase classification
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)